ABSTRACT
Objective To analyze the characteristics and the differences of body composition in Yi of Sichuan, Guizhou and Yunnan. Methods Stature, body mass and body composition of 1556 Yi(male 757 case, famale 799 case) adults from Sichuan, Guizhou and Yunnan were investigated based on Anthropometric Method and the standard of Tanita company. Results The body mass index and percent body fat of Yi nationality people from Sichuan were significantly higher than that of those from Yunnan and Guizhou. The overall muscle and limb muscles of Yi nationality people from Sichuan were more developed than that of those from Sichuan and Yunnan. Yi nationality people from Sichuan, Yunnan and Guizhou all had the characters that muscle mass in right limb was higher than that in left. Conclusion Yi nationality people from Sichuan, Yunnan and Guizhou have great difference in body composition because of the diet and labour intensity.
ABSTRACT
Garcinia, a kind of dry resin secreted by Garcinia hanburyi Hook. F. G., is a traditional Chinese medicine with various biological functions such as detoxification, anti-inflammatory, and anthelmintic activities. Recent studies suggest that garcinia has potential anticancer activity. Increasing evidences indicate that the main active monomer gambogic acid isolated from garcinia can inhibit the growth of various cancer cells. Neogambogic acid is an isolated compound with a similar chemical structure as gambogic acid. Preliminary studies show that the neogambogic acid can selectively inhibit the growth of various cancer cells, and has a broader antitumor activity and lower toxicity than gambogic acid. In this review, we summarize the advances made in the investigation of the anti-tumor effect of neogambogic acid in recent years.
Subject(s)
Animals , Humans , Antineoplastic Agents, Phytogenic , Chemistry , Garcinia , Chemistry , Neoplasms , Drug Therapy , Plant Extracts , Chemistry , Xanthenes , ChemistryABSTRACT
Garcinia, a kind of dry resin secreted by Garcinia hanburyi Hook. F. G., is a traditional Chinese medicine with various biological functions such as detoxification, anti-inflammatory, and anthelmintic activities. Recent studies suggest that garcinia has potential anticancer activity. Increasing evidences indicate that the main active monomer gambogic acid isolated from garcinia can inhibit the growth of various cancer cells. Neogambogic acid is an isolated compound with a similar chemical structure as gambogic acid. Preliminary studies show that the neogambogic acid can selectively inhibit the growth of various cancer cells, and has a broader antitumor activity and lower toxicity than gambogic acid. In this review, we summarize the advances made in the investigation of the anti-tumor effect of neogambogic acid in recent years.
Subject(s)
Animals , Humans , Antineoplastic Agents, Phytogenic , Chemistry , Garcinia , Chemistry , Neoplasms , Drug Therapy , Plant Extracts , Chemistry , Xanthenes , ChemistryABSTRACT
<p><b>BACKGROUND</b>Platinum-based chemotherapeutics are the most common regimens for advanced non-small-cell lung cancer (NSCLC) patients, and genetic factors are thought to represent important determinants of drug efficacy. We prospectively assessed the status of the XPC Ala499Val and Lys939Gln gene polymorphisms and investigated whether these SNPs can predict the response to cisplatin/carboplatin-based regimens in advanced NSCLC patients in a Chinese population.</p><p><b>METHODS</b>The treatment outcomes of 96 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. The polymorphic status of xeroderma pigmentosum group C (XPC) gene was genotyped by the 3-D polyacrylamide gel-based DNA microarray method.</p><p><b>RESULTS</b>The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P = 0.022). The heterozygous A/C genotype carriers had a poorer response rate than the wild A/A genotype carriers in stage III (OR, 0.074; 95%CI, 0.008 - 0.704; P = 0.023). The XPC Ala499Val polymorphisms were not associated with response to platinum-based chemotherapy.</p><p><b>CONCLUSION</b>Polymorphisms of the XPC gene, Lys939Gln, may be a predictive marker of treatment response for advanced NSCLC patients in stage III.</p>